SEC Tracker
Get the app

Acadia Pharmaceuticals ACAD

Acadia Pharmaceuticals reports $342.29 million revenue for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $342.29 million for the three months ended Sep 30, 2026
  2. Net income: $53.52 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $322.37 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Acadia Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  2. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  3. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  4. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  5. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.